A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.
“We are extremely lucky to have someone like Manny join our team. The breadth of his experience and his expertise will help Green Dot achieve our goals for the future, as we approach our 25th ...